MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 577015 | Name: Fexofenadine dihydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fexofenadine dihydrate is an antihistamine pharmaceutical drug used in the treatment of allergy symptoms, such as hay fever, nasal congestion, and urticaria. Fexofenadine is classified as a second-generation antihistamine because it is less able to pass the blood-brain barrier and cause sedation, compared to a first-generation antihistamines.

Chemical Structure

Fexofenadine dihydrate
Fexofenadine dihydrate
CAS#885946-90-7 (dihydrate)

Theoretical Analysis

MedKoo Cat#: 577015

Name: Fexofenadine dihydrate

CAS#: 885946-90-7 (dihydrate)

Chemical Formula: C32H43NO6

Exact Mass: 537.3090

Molecular Weight: 537.70

Elemental Analysis: C, 71.48; H, 8.06; N, 2.60; O, 17.85

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
83799-24-0 (free base) 153439-40-8 (HCl) 885946-90-7 (dihydrate)
Synonym
Fexofenadine dihydrate
IUPAC/Chemical Name
2-(4-{1-Hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoic acid dihydrate
InChi Key
PBHJQUWFAKHMIX-UHFFFAOYSA-N
InChi Code
InChI=1S/C32H39NO4.2H2O/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27;;/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36);2*1H2
SMILES Code
CC(C)(C1=CC=C(C(O)CCCN2CCC(C(C3=CC=CC=C3)(O)C4=CC=CC=C4)CC2)C=C1)C(O)=O.[H]O[H].[H]O[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 537.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Yao M, Srinivas NR. Quantification of fexofenadine in biological matrices: a review of bioanalytical methods. Biomed Chromatogr. 2012 Aug;26(8):942-61. doi: 10.1002/bmc.2712. Epub 2012 Feb 21. Review. PubMed PMID: 22354834. 2: Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, Gómez RM, Canonica GW, Baena-Cagnani CE. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Arch Allergy Immunol. 2011;156(1):1-15. Review. PubMed PMID: 21969990. 3: Miura M, Uno T. Clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):69-74. doi: 10.1517/17425250903382615. Review. PubMed PMID: 19947891. 4: Smith SM, Gums JG. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):813-22. doi: 10.1517/17425250903044967. Review. PubMed PMID: 19545214. 5: Bachert C. A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. doi: 10.1016/j.clinthera.2009.05.017. Review. PubMed PMID: 19539095. 6: Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. Review. PubMed PMID: 18336052. 7: Mansfield LE. Fexofenadine in pediatrics: oral tablet and suspension formulations. Expert Opin Pharmacother. 2008 Feb;9(2):329-37. doi: 10.1517/14656566.9.2.329 . Review. PubMed PMID: 18201155. 8: Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R D. 2007;8(5):301-14. Review. PubMed PMID: 17767395. 9: Mansfield LE. Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis. Expert Opin Pharmacother. 2006 May;7(7):941-51. Review. PubMed PMID: 16634716. 10: Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004 Aug;18(4):399-411. Review. PubMed PMID: 15312146. 11: Ciprandi G, Tosca MA, Cosentino C, Riccio AM, Passalacqua G, Canonica GW. Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S78-82. Review. PubMed PMID: 14530792. 12: Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S69-77. Review. PubMed PMID: 14530791. 13: Kawashima M, Harada S, Tango T. Review of fexofenadine in the treatment of chronic idiopathic urticaria. Int J Dermatol. 2002 Oct;41(10):701-6. Review. PubMed PMID: 12390200. 14: Amichai B, Grunwald MH, Brenner L. Fexofenadine hydrochloride--a new anti-histaminic drug. Isr Med Assoc J. 2001 Mar;3(3):207-9. Review. PubMed PMID: 11303380. 15: Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy. 1999 Jul;29 Suppl 3:163-70; discussion 171-3. Review. PubMed PMID: 10444232. 16: Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R. Cardiovascular safety of fexofenadine HCl. Am J Cardiol. 1999 May 15;83(10):1451-4. Review. PubMed PMID: 10335761. 17: Markham A, Wagstaff AJ. Fexofenadine. Drugs. 1998 Feb;55(2):269-74; discussion 275-6. Review. PubMed PMID: 9506246.